BG-8967 Bivalirudin

Bivalirudin, also known as BG-8967, is a specific and reversible direct thrombin inhibitor (DTI). Chemically, it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech Hirudo medicinalis). Bivalirudin overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin.

Properties
Appearance & Physical State: white to off-white powder
Density: 1.52 g/cm3
Refractive Index: 1.675

Related Prodcuts:

Icatibant; Lanreotide; Nesiritide; Leuprolide Acetate; Liraglutide; Lypressin; Atosiban; Oxytocin; Pasireotide; Pramlintide Acetate; Calcitonin Salmon; Alarelin Acetate; Sincalide; Somatostatin Acetate; Glucagon HCl

1: Esteve-Pastor MA, Hernández-Romero D, Valdés M, Marín F. New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor? Molecules. 2016 Feb 27;21(3). pii: E284. doi: 10.3390/molecules21030284. Review. PubMed PMID: 26927051.

2: Zhang S, Gao W, Li H, Zou M, Sun S, Ba Y, Liu Y, Cheng G. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Int J Cardiol. 2016 Apr 15;209:87-95. doi: 10.1016/j.ijcard.2016.01.206. Epub 2016 Jan 26. Review. PubMed PMID: 26882192.